Inmedix, a boutique biotech company, is now working on commercializing its second major patent. The first patent was acquired by a large pharmaceutical company at an historic valuation.
Inmedix is a team of scientists, business people, and industry professionals that work to bring unique, profound discoveries to reduce the suffering of patients, particularly those afflicted by autoimmune disease.
Not only has Inmedix conducted several clinical research studies but many other independent studies have been published in our field of discovery further validating the science behind our work.
With the initial investment we are seeking, we will begin the last research study needed to obtain FDA approval and commercialize our technology ( in about 2.5 years). We look forward to helping suffering patients bring their disease to remission with existing treatments. Contact us at tvs@inmedix.com to obtain more information.
Inmedix is on the forefront of science that will improve the way disease is managed, in particular, rheumatoid arthritis (RA). Rheumatoid arthritis is a debilitating autoimmune disease that permanently damages affected joints if left untreated or treated ineffectively.
Currently, only 27% of RA patients receive a remission of symptoms as a result of therapeutic treatment. Inmedix’s discovery, which is protected by an issued patent, helps rheumatologists achieve a greater than 65% in remission of patient RA symptoms – an increase of more than 140%. Hundreds of thousands can be helped.
We have proven through our research of 5 research studies and 243 patients, along with rheumatology clinical outcomes, that our technology can bring massive reduction in suffering to RA patients and improve therapeutic outcomes to a high remission rate.
Email tvs@inmedix.com to learn more about participating in this life-changing opportunity.
Andrew J Holman MD – CEO, CMO and Co-Founder. Associate Clinical Professor of Medicine, University of Washington. 20+ year clinical and 15+ year rheumatology research career experience with 16 lead author published papers, 25 lead author published abstracts. Designed and completed 16 clinical studies involving 1550 patients for Inmedix as well as led FDA negotiations.